BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jul 26, 2004
 |  BioCentury  |  Strategy

Redeploying to repurpose

With declining revenues from its information and contract study services, Gene Logic Inc. last week announced an expanded service model based on technology acquired from Millennium Pharmaceuticals Inc. GLGC says the acquisition completes its goal of being able to offer a complete line of drug discovery and development services throughout the value chain. For MLNM, the deal allows it to get paid for offloading unnecessary assets, including two shelved metabolic programs, as part of its strategy to focus resources on downstream development.

GLGC acquired a set of technology from MLNM, including in vivo compound imaging, in vitro pathway screening, predictive and genetic ADME capabilities and metabolomic technology, plus a team of six researchers.

GLGC's offerings for drug discovery already include its BioExpress Module database of gene expression-based information, ToxExpress reference database of gene expression data from in vivo and in vitro toxicology studies, Ascenta System web-based database of microarray gene expression profiles, and Genesis 2.0 gene expression data management software program.

In March 2003, the company acquired TheraImmune Research Corp., which provided GLGC with preclinical and early-stage...

Read the full 877 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >